Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ImCheck Therapeutics SAS

News headline image
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Appoints Stephan Braun as Chief Medical Officer
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
From ImCheck Therapeutics SAS
Via GlobeNewswire
News headline image
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
From ImCheck Therapeutics SAS
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.